Pharma

Taking stock of the drug industry, from the lab to the medicine chest

Pharmalot

Pharmalittle: Compounders getting pushback; fast-acting flu drug shows potential

By Elizabeth Cooney

Biotech

Ex-InVivo chief’s story is a cautionary tale for the go-go biotech world

By Jonathan Saltzman — Boston Globe

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

AmerisourceBergen
Pharmalot

Once again, AmerisourceBergen scrambles to fix a troubled compounding facility

By Ed Silverman

Pharmalot

Pharmalittle: Trump hiring restrictions hurt FDA; Purdue family member has patent for addiction treatment

By Ed Silverman

Tuberculosis patient
Pharmalot

U.N. global declaration on TB passes key hurdle as U.S. and others reach a compromise

By Ed Silverman

Close up of saline solution drip
Pharmalot

The hospital exec behind the new generic maker: We’re trying to bring ‘sanity’ to the market

By Ed Silverman

Pharmalot

Pharmalittle: Novartis sells part of its U.S. generic business; Glaxo to lay off 650 U.S. employees

By Ed Silverman

President Trump Delivers Remarks On Lowering Drug Prices In Rose Garden
Pharmalot

Most Americans don’t believe Trump’s tough talk will lower drug prices

By Ed Silverman

Pharmalot

Pharmalittle: Bayer to overhaul R&D and cut jobs; FDA on pace for record number of generic approvals

By Ed Silverman

Novartis Colombia
Pharmalot

After dropping the price, Novartis wins U.K. coverage for its CAR-T drug to treat childhood leukemia

By Ed Silverman

Pharmalot

California edges closer to adopting a take-back law for medicines and needles

By Ed Silverman

Pharmalot

Sanofi pays $25 million to settle charges of bribing doctors and officials in the Mideast

By Ed Silverman

Pharmalot

Pharmalittle: Former Glaxo scientist pleads guilty to stealing trade secrets; Novartis to streamline production

By Ed Silverman

Pharmalot

Judge tosses pharma lawsuit designed to thwart California transparency law

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Novartis and feds duel over kickback case; FDA widens probe into heart drugs over cancer link

By Ed Silverman

CVS Miami
Pharmalot

CVS exec: Our new reliance on cost effectiveness should make drug makers ‘think about launch prices’

By Ed Silverman

Racial bias Pain Management
Pharmalot

FDA widening probe into heart drugs linked to cancer risk

By Ed Silverman

Hepatitis Drugs
Pharmalot

The new Chilean health minister endorses compulsory licenses for hepatitis C drugs

By Ed Silverman

Seema Verma CAR-T
Pharmalot

To lower drug costs, CMS wants Medicare Part D plans to loosen formularies

By Ed Silverman

Pharmalot

Pharmalittle: Biotech boom pays off for Wall Street analysts; Canadian province sues opioid makers

By Ed Silverman

Abilify-MyCite illustration
Pharma

At $1,650 per month, the first digital pill will soon roll out to certain Medicaid patients with mental illness

By Rebecca Robbins

Pfizer
Pharmalot

Pfizer encounters yet another setback at a troubled manufacturing plant

By Ed Silverman

Vials
Pharmalot

Trade deal between U.S. and Mexico is criticized for allowing high drug prices to continue

By Ed Silverman

Pharmalot

Pharmalittle: Emergent buys Narcan but promises to maintain pricing; Novartis vows Alcon spin off on track despite a recall

By Ed Silverman

Alex Azar - for first opinion
Pharmalot

Watchdog asks ethics officials to probe Azar over industry ties and views on rebates

By Ed Silverman

Gilead Sciences
Pharmalot

U.K.’s cost-effectiveness watchdog rejects Gilead’s CAR-T therapy for government coverage

By Ed Silverman

Pharmalot

Pharmalittle: U.K. cost watchdog rejects Gilead CAR-T drug; Akcea gets a complete response letter

By Ed Silverman

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy